Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response

Abstract Current influenza vaccines have a suboptimal effectiveness. The introduction of a novel A/H1N1 influenza virus in 2009 (H1N1pdm09) provided a unique opportunity to study the humoral response to the AS03-adjuvanted H1N1pdm09 vaccine and repeated annual vaccination with the homologous virus i...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anders Madsen, Åsne Jul-Larsen, Mai-Chi Trieu, Florian Krammer, Rebecca J. Cox
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/289f3ecc96424a40be207c2772ea704a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:289f3ecc96424a40be207c2772ea704a
record_format	dspace
spelling	oai:doaj.org-article:289f3ecc96424a40be207c2772ea704a2021-12-02T13:26:37ZPersistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response10.1038/s41541-021-00308-52059-0105https://doaj.org/article/289f3ecc96424a40be207c2772ea704a2021-04-01T00:00:00Zhttps://doi.org/10.1038/s41541-021-00308-5https://doaj.org/toc/2059-0105Abstract Current influenza vaccines have a suboptimal effectiveness. The introduction of a novel A/H1N1 influenza virus in 2009 (H1N1pdm09) provided a unique opportunity to study the humoral response to the AS03-adjuvanted H1N1pdm09 vaccine and repeated annual vaccination with the homologous virus in subsequent influenza seasons. Thirty-two HCWs immunized with the AS03-adjuvanted H1N1pdm09 vaccine in 2009 were divided into four groups based on the longevity of their antibody responses (persistently high or transient), and whether they were repeatedly annually vaccinated in the subsequent four influenza seasons or not. Serological assays were utilized to measure the quantity, quality and functionality of antibodies targeting the major surface glycoprotein hemagglutinin (HA). Persistent high responders (hemagglutination inhibition (HI) titre ≥ 80 at 12 months after H1N1pdm09 vaccination) had protective levels of HI antibodies throughout the study period. In addition, the quality and functionality of these antibodies were greater than the individuals who had a transient antibody response to the pandemic vaccine (HI titre < 40 at 12 months after H1N1pdm09 vaccination). All groups had similar levels of antibodies towards the conserved HA stalk domain. The level of HA head-specific antibodies gradually increased over time with annual vaccination in the transient responders. The AS03-adjuvanted H1N1pdm09 vaccine elicited a robust humoral response that persisted up to 5 years in some individuals. Seasonal annual vaccination boosted the HA-antibodies over time in individuals with a transient response to the pandemic H1N1pdm09 vaccine.Anders MadsenÅsne Jul-LarsenMai-Chi TrieuFlorian KrammerRebecca J. CoxNature PortfolioarticleImmunologic diseases. AllergyRC581-607Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENnpj Vaccines, Vol 6, Iss 1, Pp 1-6 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Immunologic diseases. Allergy RC581-607 Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Anders Madsen Åsne Jul-Larsen Mai-Chi Trieu Florian Krammer Rebecca J. Cox Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
description	Abstract Current influenza vaccines have a suboptimal effectiveness. The introduction of a novel A/H1N1 influenza virus in 2009 (H1N1pdm09) provided a unique opportunity to study the humoral response to the AS03-adjuvanted H1N1pdm09 vaccine and repeated annual vaccination with the homologous virus in subsequent influenza seasons. Thirty-two HCWs immunized with the AS03-adjuvanted H1N1pdm09 vaccine in 2009 were divided into four groups based on the longevity of their antibody responses (persistently high or transient), and whether they were repeatedly annually vaccinated in the subsequent four influenza seasons or not. Serological assays were utilized to measure the quantity, quality and functionality of antibodies targeting the major surface glycoprotein hemagglutinin (HA). Persistent high responders (hemagglutination inhibition (HI) titre ≥ 80 at 12 months after H1N1pdm09 vaccination) had protective levels of HI antibodies throughout the study period. In addition, the quality and functionality of these antibodies were greater than the individuals who had a transient antibody response to the pandemic vaccine (HI titre < 40 at 12 months after H1N1pdm09 vaccination). All groups had similar levels of antibodies towards the conserved HA stalk domain. The level of HA head-specific antibodies gradually increased over time with annual vaccination in the transient responders. The AS03-adjuvanted H1N1pdm09 vaccine elicited a robust humoral response that persisted up to 5 years in some individuals. Seasonal annual vaccination boosted the HA-antibodies over time in individuals with a transient response to the pandemic H1N1pdm09 vaccine.
format	article
author	Anders Madsen Åsne Jul-Larsen Mai-Chi Trieu Florian Krammer Rebecca J. Cox
author_facet	Anders Madsen Åsne Jul-Larsen Mai-Chi Trieu Florian Krammer Rebecca J. Cox
author_sort	Anders Madsen
title	Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
title_short	Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
title_full	Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
title_fullStr	Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
title_full_unstemmed	Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response
title_sort	persistently high antibody responses after as03-adjuvanted h1n1pdm09 vaccine: dissecting the ha specific antibody response
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/289f3ecc96424a40be207c2772ea704a
work_keys_str_mv	AT andersmadsen persistentlyhighantibodyresponsesafteras03adjuvantedh1n1pdm09vaccinedissectingthehaspecificantibodyresponse AT asnejullarsen persistentlyhighantibodyresponsesafteras03adjuvantedh1n1pdm09vaccinedissectingthehaspecificantibodyresponse AT maichitrieu persistentlyhighantibodyresponsesafteras03adjuvantedh1n1pdm09vaccinedissectingthehaspecificantibodyresponse AT floriankrammer persistentlyhighantibodyresponsesafteras03adjuvantedh1n1pdm09vaccinedissectingthehaspecificantibodyresponse AT rebeccajcox persistentlyhighantibodyresponsesafteras03adjuvantedh1n1pdm09vaccinedissectingthehaspecificantibodyresponse
_version_	1718393019159281664

Persistently high antibody responses after AS03-adjuvanted H1N1pdm09 vaccine: Dissecting the HA specific antibody response

Ejemplares similares